文拉法辛缓释剂治疗抑郁症急性期患者临床疗效的开放性研究

目的 评价5-羟色胺及去甲肾上腺素双重再摄取抑制剂文拉法辛缓释剂治疗抑郁症急性期门诊患者的临床疗效。方法 对11所医院的217例抑郁症急性期门诊患者予以文拉法辛缓释剂治疗，75mg／d，疗程共8周，治疗前后采用汉密尔顿抑郁量表(HAMD)和汉密尔顿焦虑量表(HAMA)评分观察疗效，以及观察相关实验室检查及记录不良反应。结果 文拉法辛缓释剂治疗急性期门诊抑郁症的临床治愈率和总有效率分别为60.4％和89.4％，HAMD和HAMA治疗前后的减分率分别为76．7％和77.1％；不良反应出现率为27.2％，其中89.6％的患者的不良反应在疗程结束时消失。结论 文拉法辛缓释剂能有效缓解抑郁和焦虑症状，对大多数门诊抑郁症患者在急性期治疗后能达到临床治愈，并有较好的耐受性和依从性。

Treatment of depressive outpatient with venlafaxine:an open clinical trial

Objective It aimed to assess the clinical effects of Venlafaxine XR(Efexor XR) treatment of depressive outpatients. Methods In the open-label study, 217 depressed outpatients from 11 hospitals were treated with Venlafaxine XR for 8 weeks. All participants were examined with the Hamilton Rating Scale of Depression (HAMD) and Hamilton Rating Scale of Anxiety (HAMA) before and after treatment. And side effects were recorded as well. Results After 8-week treatment, 89.4% of the patients were improved, and 60.4% had remission. The reduction rates of the HAMD and HAMA scores were 76.7% and 77.1%, respectively. Altogether 59 cases (27.2%) had some side effects during the treatment, but 89.6% of them disappeared when at end of the trial. Conclusions This study shows Venlafaxine XR can effectively treat depressive and anxiety symptoms.